Although AAT production occurs mainly in hepatocytes, it also occurs in intestinal cells, alveoli, macrophages, neutrophils, and the cornea.3 The protein is released into the bloodstream and acts as a protector against neutrophil elastase, mainly in the lungs.3 Its half-life is 3-5 days, and serum concentrations vary little in normal individuals, although they can be elevated during inflammatory processes.3 Although pulmonary densitometry appears to be the most sensitive measure of emphysema progression, it should not be used in routine clinical practice to monitor patients. Monitoring lung function, especially through spirometry, is essential, because it provides information on the progression of the disease.
If you’ve been diagnosed with Alpha-1, see your provider if you have any new symptoms or questions about your care, or if you’re having trouble managing your symptoms. Early diagnosis is important, so if you have COPD or asthma, ask your provider if you should get an Alpha-1 test. See your provider if you have symptoms of Alpha-1 or if a family member has Alpha-1. Follow your provider’s recommendations for other ways to stay healthy and manage your symptoms. This includes smoking, lung irritants, alcohol and certain medications. But that doesn’t mean you’ll develop the diseases it can cause. Some people live a normal life span and some have life-threatening complications.
Desmosine and isodesmosine (lung elastin degradation products usually elevated in COPD patients but also in AATD patients) were reduced after long-term intravenous AT and possibly with nebulized therapy52. Use of CT densitometry in disease monitoring has been vital in proving an effect of AT in emphysema10, and lower CT density has also been related to mortality in AATD patients with basal emphysema, while FEV1 and DLCO alone have a weaker relationship11. Although these are rare associations, they are plausible, since AAT is anti-inflammatory and immunomodulatory47,49; thus, in AATD, enhanced risk of inflammatory and autoimmune diseases could occur. CB, as part of the spectrum of neutrophilic inflammation in the lungs, might be one of the clinical features that should draw attention to AATD diagnosis2. AATD lung disease is characterized by basal pan-lobular emphysema at an early age, though a range of other phenotypes have been recognized (Figure 2).
In patients with progressive lung disease and a gradual loss of function, the symptoms may be underestimated. The characteristics that distinguish AATD-related COPD in nonsmokers or smokers without occupational risk factors from COPD caused by smoking (unrelated to AATD) are the early onset of symptoms, panacinar emphysema, and a predominance of radiological changes at baseline.5 However, the "classic" presentation of smoking-related COPD also occurs in patients with AATD and should not rule out the possibility in such patients.47,48 It is important to emphasize that up to 37% of individuals with severe AATD have emphysema predominantly in the upper lobes.19,49 As demonstrated in previous studies,3,31,32 AATD is a heterogeneous condition in which the combination of the genotype with low serum AAT concentration and risk factors are fundamental for the emergence and progression of its clinical and functional manifestations. AAT-AT has produced beneficial consequences, like ameliorating lung function decline and emphysema progression, prolonging survival, and delaying the decline in quality of life, especially in severe AATD, i.e. in ZZ or Z null patients14,56,66–68. Regardless of genotype, additional education about moderation of alcohol consumption should be considered because of the increased risk of liver disease among individuals with AATD.
A diagnosis of AATD has several immediate impacts,75 such as the need to test family members; the opportunity to implement educational measures; early intervention regarding smoking habits; advising patients about environmental and occupational exposures; and the opportunity to consider specific AATD treatment. To elucidate this relationship, the plasma of a 14-year-old boy who died of a hemorrhagic disorder was studied, and a variant of AAT was found in which the methionine at position 358 was replaced by an arginine, converting the normal function of AAT as an elastase inhibitor to that of a thrombin inhibitor.72 The data regarding the association between AATD and inflammatory bowel disease are conflicting and cannot be legitimized. Noninvasive liver evaluation through biochemical studies, transient hepatic elastography, and the determination of phenotypes/genotypes should be performed routinely in individuals with AATD.5 Given the nature and risk of complications, liver biopsy is reserved for selected cases only. Although smoking continues to be the main risk factor for lung disease, other factors, including predisposing familial conditions, respiratory infections, and exposure to environmental or occupational pollutants, which also increase inflammation and elastase in the airways and alveoli, have increasingly been studied and valued.31-33 Such registries allow us to understand AATD in a given location, to characterize patients, and to establish programs aimed at early diagnosis, as well as enabling the expansion of knowledge about the natural history of the disease. Patients with pulmonary manifestations should be monitored according to the recommendations for COPD.11 In some cases, such patients should be referred for specific treatment with AAT replacement.12

Gender: Female

Social links